By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel is divided on the impact of SpaceX's IPO, with some arguing it could 'suck the oxygen' out of the market, while others believe it may attract new capital and help other listings. The key risk is the potential compression of valuation multiples for existing space-tech and AI peers, while the opportunity lies in the possibility of attracting new long-term allocators.
Risk: Valuation multiple compression for existing space-tech and AI peers
Opportunity: Attracting new long-term allocators
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
SpaceX's imminent initial public offering is set to be the biggest stock debut in history — but the sheer scale of the launch could squeeze investor demand for other new listings, market watchers suggest.
Samuel Kerr, global head of equity capital markets at Mergermarket, said SpaceX's long-awaited listing, expected June 12, comes as Europe's IPO market struggles to build momentum, in sharp contrast to the "completely booming" U.S. market.
With a potential $75 billion IPO and a market valuation of $1.75 trillion, SpaceX's debut offering is "otherworldly," Kerr said. Such a listing would "dwarf" other recent debuts, including AI chipmaker Cerebras Systems, whose blockbuster IPO last week pushed its market cap to about $95 billion.
"There's a possibility it could be a negative for the whole global IPO market," Kerr told CNBC's "Europe Early Edition" on Tuesday.
He noted typical IPOs aim to be around five-times covered ahead of pricing, meaning demand for the SpaceX offering would likely need to be "well in excess" of $75 billion.
It has the potential to "really suck all the oxygen out the room for anybody else," Kerr explained. "Everybody's eyes are going to be on SpaceX."
Given the scale of capital the deal is expected to absorb from the global equity capital markets investor base — with investors potentially allocating significant orders to the listing — "almost nothing's going to want to be in the market at the same time," he added.
Elon Musk's company is expected to unveil its IPO prospectus in the coming days.
## 'Negative cocktail'
The landmark debut — and the potential capacity squeeze caused by other blockbuster listings in the pipeline, such as OpenAI — further complicates the outlook for Europe's IPO space, which is already grappling with ongoing bond market volatility and the prospect of looming interest rate hikes.
Kerr said macroeconomic pressures, coupled with sustained uncertainty surrounding the Iran war, its impact on supply costs and rising energy prices, as well as structural weaknesses in the European IPO space — where many new listings underperformed last year — amount to a "pretty negative cocktail" for the market overall.
"Global interest rate rises are a big problem for the IPO market… another ingredient to that negative cocktail is higher bond prices," he added.
"We were not really expecting an incredibly busy first half of the year, but anything that we were expecting to see in the first half of the year has now been pretty much postponed, at least to the second half."
Looking ahead, Salman Ahmed, global head of macro and strategic asset allocation at Fidelity International, warned that a wave of mega IPOs could temporarily drain liquidity from broader equity markets.
With SpaceX, OpenAI and Anthropic all in the frame, Ahmed said the sheer size of upcoming deals could create a major "supply event" for equities, forcing portfolio managers to rebalance positions and potentially triggering a period of market "indigestion," particularly in heavily concentrated U.S. stock markets where gains have been dominated by a handful of large-cap winners.
"They'll have to suck in a lot of capital from the system, and that's why I think there's another reason we have to be careful about the winners right now, because that's where the capital is going to be pulled from to finance these mega IPOs."
*— CNBC's Lee Ying Shan contributed to this story.*
Four leading AI models discuss this article
"Macro factors and Europe's structural weaknesses will matter more for its IPO recovery than any single U.S. mega-deal."
SpaceX's expected June 12 IPO at $75 billion could absorb outsized allocations from global funds already eyeing U.S. names, leaving less dry powder for European issuers already facing 2024 underperformance and structural illiquidity. The article correctly flags the risk of a 'negative cocktail' from rate volatility and Iran-related energy shocks, but understates how a $1.75 trillion valuation debut might instead widen the bid for high-growth tech broadly once pricing clears. Europe's pipeline delay to H2 is real, yet the bigger variable remains whether post-SpaceX sentiment lifts follow-on deals or simply highlights the continent's chronic lack of scale.
Mega-cap IPOs have repeatedly coincided with subsequent equity-market rallies by validating valuations and pulling in incremental capital; Europe's IPO drought could therefore end faster in H2 once the headline event passes rather than being permanently sidelined.
"SpaceX's IPO will create short-term rebalancing pressure in U.S. large-cap stocks, but the 'global oxygen squeeze' narrative conflates unrelated European structural headwinds with a liquidity event that may actually be demand-positive."
The article conflates two distinct risks that may not materialize equally. Yes, a $75B SpaceX IPO absorbs capital—but 'oxygen squeeze' assumes fixed investor pools and sequential timing. In reality: (1) mega-IPOs often *attract* new capital rather than cannibalize it; (2) the article provides zero evidence OpenAI or Anthropic are actually pricing in H1 2025; (3) European weakness predates SpaceX and reflects structural issues (regulatory, rates, underperformance) unrelated to U.S. mega-cap debuts. The real risk is narrower: U.S. mega-cap concentration could worsen if portfolio rebalancing pulls from mid/small-cap, but that's a domestic U.S. problem, not a global IPO market collapse.
SpaceX's IPO could actually *validate* equity markets and unlock pent-up demand for other listings—mega-IPOs historically precede IPO waves, not droughts. The article assumes scarcity of capital; post-2024 rally, institutional dry powder is substantial.
"The SpaceX IPO will likely trigger a valuation reset for smaller space and AI peers as institutional capital rotates into the new, higher-quality market leader."
The narrative that a SpaceX IPO will 'suck the oxygen' out of the market assumes a zero-sum game for liquidity that ignores the reality of institutional mandate-driven capital. While a $75 billion raise is massive, it represents a 'must-own' asset for growth-oriented funds, likely triggering portfolio rebalancing rather than a net liquidity drain. The real risk isn't the IPO itself, but the valuation multiple compression it might force on existing space-tech and AI peers. If SpaceX hits the market at a 20x-30x revenue multiple, it will highlight the overvaluation of smaller, less-liquid SPACs and earlier-stage aerospace firms, causing a painful repricing across the broader sector as capital rotates into the new market leader.
A massive SpaceX IPO could actually act as a market catalyst, attracting significant inflows of dormant retail and institutional cash that has been sitting on the sidelines waiting for a 'generational' growth story.
"The real determinant is demand quality and pricing discipline, not merely deal size."
Strong case against the doom: Mega IPOs don’t automatically 'suck oxygen' out of the room. They can magnetize new pools of long-term allocators (global tech funds, sovereign wealth, crossover funds) and create a pricing reference that helps other listings, not just crowd them out. The real risk is mispricing, demand mix, and the structure (lockups, dual-class) that can affect secondary liquidity. SpaceX’s impact will hinge on whether demand is broad and price discovery credible; if not, the initial frenzy could reverse and spook other issuers. The missing context: valuation debate, revenue trajectory, regulatory path, and the actual calendar optics for Europe vs US. Near term: heightened volatility; longer term: uncertain.
Counterpoint: Even if mega-IPOs draw new capital, marginal liquidity for smaller IPOs tends to shrink as managers reallocate risk budgets around one mega deal; if SpaceX is priced richly or underperforms, the crowding could accelerate a pullback in the rest of the calendar.
"SpaceX pricing will force European issuers into a valuation reset before any H2 rebound."
Claude separates the capital-attraction dynamic from cannibalization but underplays the sequencing risk: once SpaceX prices in June, European mandates may pause H1 allocations to reassess benchmarks against a new $75B tech anchor. This timing link to Gemini's multiple-compression point means smaller issuers could face wider bid-ask spreads in July even if overall dry powder stays intact.
"SpaceX's June timing amplifies existing European headwinds but doesn't fundamentally alter the capital supply equation."
Grok's 'sequencing risk' is real but overstated. European mandate reassessment happens regardless of SpaceX; the June IPO doesn't *cause* European weakness, it just coincides with it. The bid-ask spread widening in July is plausible for illiquid mid-caps, but that's a liquidity structure problem, not proof SpaceX cannibalized capital. Nobody's addressed whether European issuers actually *want* to price in H1—if they're already deferring to H2 due to rates and underperformance, SpaceX timing is correlation, not causation.
"Passive index inclusion for a $75B+ IPO forces mechanical selling of smaller peers, creating a structural liquidity drain unrelated to investor sentiment."
Claude is right about correlation, but both Claude and Grok ignore the 'starving the index' effect. If SpaceX enters the S&P 500 or Nasdaq 100, passive flows must buy regardless of valuation, forcing an immediate, mechanical sell-off of smaller constituents to fund the purchase. This isn't just about 'sentiment' or 'sequencing'; it's a structural liquidity drain on the broader market that will disproportionately punish the mid-cap growth stocks currently trying to launch their own IPOs.
"SpaceX's impact on mid-cap IPO liquidity hinges on benchmark inclusion; absent index-weighted flows, the 'starving the index' risk is overstated."
Gemini's 'starving the index' claim hinges on SpaceX joining a benchmark. My take: passive inflows won’t mechanically drain mid-cap IPOs unless SpaceX actually triggers a large ETF reweighting. In practice, funds can absorb a mega deal and still rotate into smaller growth names; the net effect depends on (1) whether SpaceX is index-eligible, (2) tracking-error constraints, and (3) whether capital shifts are US- or Europe-led. Without benchmark inclusion, the risk feels overstated.
The panel is divided on the impact of SpaceX's IPO, with some arguing it could 'suck the oxygen' out of the market, while others believe it may attract new capital and help other listings. The key risk is the potential compression of valuation multiples for existing space-tech and AI peers, while the opportunity lies in the possibility of attracting new long-term allocators.
Attracting new long-term allocators
Valuation multiple compression for existing space-tech and AI peers